PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25065563-5 2015 We hypothesized that the combination of neoadjuvant nab-paclitaxel followed by vinorelbine could represent a nonanthracycline-based treatment option for early-stage Her2-overexpressing breast cancer. nab 52-55 erb-b2 receptor tyrosine kinase 2 Homo sapiens 165-169 25678799-0 2015 Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases. nab 12-15 erb-b2 receptor tyrosine kinase 2 Homo sapiens 83-87 25678799-7 2015 Herein, we report a lengthy progression-free survival with the combination trastuzumab/nanoparticle albumin-bound (nab)-paclitaxel in a heavily pretreated HER2-positive BC patient with BM. nab 115-118 erb-b2 receptor tyrosine kinase 2 Homo sapiens 155-159 25678799-12 2015 In conclusion, weekly nab-paclitaxel plus trastuzumab may represent a valuable option in the treatment of HER2-positive MBC with BM after radiotherapy and is effective and associated with a good toxicity profile, even in heavily pretreated patients. nab 22-25 erb-b2 receptor tyrosine kinase 2 Homo sapiens 106-110 20585851-0 2010 Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. nab 37-40 erb-b2 receptor tyrosine kinase 2 Homo sapiens 122-126 21887460-4 2011 To elucidate whether combined treatment with NaB and trastuzumab exerts anti-tumor effects on a HER2-overexpressing breast cancer cell line, SKBR3 cells were treated with NaB alone or in combination with trastuzumab, and the effects on proliferation and cell cycle progression were analyzed. nab 45-48 erb-b2 receptor tyrosine kinase 2 Homo sapiens 96-100 21887460-8 2011 In conclusion, trastuzumab significantly improved the antitumor effect of NaB on HER2-overexpressing breast cancer cell line in vitro. nab 74-77 erb-b2 receptor tyrosine kinase 2 Homo sapiens 81-85 21359953-10 2012 The combination of lapatinib and nab-paclitaxel was well tolerated and provided good efficacy in women with HER2 positive breast cancer. nab 33-36 erb-b2 receptor tyrosine kinase 2 Homo sapiens 108-112 32259780-2 2020 This report describes a patient with HER2-positive metastatic breast cancer with an exceptional response to trastuzumab and nab-paclitaxel who remains in complete remission several years after cessation of therapy. nab 124-127 erb-b2 receptor tyrosine kinase 2 Homo sapiens 37-41 33283132-0 2020 Measuring Tumor Epichaperome Expression Using [124I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer. nab 132-135 erb-b2 receptor tyrosine kinase 2 Homo sapiens 150-154 32436244-0 2020 A multicenter phase II trial of nab-paclitaxel and capecitabine in HER-2 negative and triple- negative advanced breast cancer: Could be an old regimen a valid approach to a changing disease? nab 32-35 erb-b2 receptor tyrosine kinase 2 Homo sapiens 67-72 32273207-0 2020 Effectiveness and Tolerability of Nab-paclitaxel in Younger versus Elderly Patients With Metastatic HR-positive/HER2-negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO. nab 34-37 erb-b2 receptor tyrosine kinase 2 Homo sapiens 112-116 32273207-9 2020 CONCLUSION: Treatment with nab-paclitaxel in first- or further-line of metastatic HR-positive/HER2-negative breast cancer resulted in similar effectiveness and safety, irrespective of age. nab 27-30 erb-b2 receptor tyrosine kinase 2 Homo sapiens 94-98 18766004-9 2008 In these HER2-positive tumors, nab-paclitaxel was equal to or better than polysorbate-based docetaxel in tumors with medium to high SPARC levels (PC3 and HT29), but not in MDA-MB-231/HER2+ tumors with low SPARC expression. nab 31-34 erb-b2 receptor tyrosine kinase 2 Homo sapiens 9-13 18766004-9 2008 In these HER2-positive tumors, nab-paclitaxel was equal to or better than polysorbate-based docetaxel in tumors with medium to high SPARC levels (PC3 and HT29), but not in MDA-MB-231/HER2+ tumors with low SPARC expression. nab 31-34 erb-b2 receptor tyrosine kinase 2 Homo sapiens 183-187 18766004-10 2008 These results demonstrated that the relative efficacy of nab-paclitaxel was significantly higher compared with polysorbate-based docetaxel in HER2-negative tumors (three of three) and in HER2-positive tumors with high levels of SPARC. nab 57-60 erb-b2 receptor tyrosine kinase 2 Homo sapiens 142-146 33117463-11 2020 Conclusions: Neoadjuvant chemotherapy using nab-PTX with trastuzumab every 3 weeks followed by FEC was suitably tolerated and associated with a high pCR rate of 55% for patients with HER2-positive breast cancer. nab 44-47 erb-b2 receptor tyrosine kinase 2 Homo sapiens 183-187 30979740-9 2019 An increased response to nab-paclitaxel was observed only in PIK3CAwt breast cancer, with univariate significance for the complete cohort (P = 0.009) and the TNBC (P = 0.013) and multivariate significance in the HER2pos subcohort (test for interaction P = 0.0074). nab 25-28 erb-b2 receptor tyrosine kinase 2 Homo sapiens 212-216 31477168-2 2019 Dual HER2 blockade with ado-trastuzumab emtansine (T-DM1) and lapatinib plus nab-paclitaxel has shown efficacy in patients with metastatic HER2-positive breast cancer. nab 77-80 erb-b2 receptor tyrosine kinase 2 Homo sapiens 5-9 29328489-11 2018 In conclusion, trastuzumab/nab-paclitaxel could mediate targeted therapy and enhance antitumor efficacy, which could represent a novel therapeutic agent for HER2-positive GC. nab 27-30 erb-b2 receptor tyrosine kinase 2 Homo sapiens 157-161 30952749-9 2019 CONCLUSION: Nab-paclitaxel plus trastuzumab followed by FEC in patients with HER2-positive operable breast cancer is considerably effective and well tolerated. nab 12-15 erb-b2 receptor tyrosine kinase 2 Homo sapiens 77-81 30460489-0 2019 Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours-the MACBETH project. nab 86-89 erb-b2 receptor tyrosine kinase 2 Homo sapiens 114-118 30389744-2 2019 Here we report a case of Takotsubo cardiomyopathy associated with the use of dual anti-HER2 therapy in a 63-year-old woman who presented to the emergency department with an 8- to 10-hour history of progressive dyspnea after completing her third cycle of pertuzumab plus trastuzumab in addition to nab-paclitaxel chemotherapy. nab 297-300 erb-b2 receptor tyrosine kinase 2 Homo sapiens 87-91 29327055-4 2018 Objective: To determine whether nab-paclitaxel improves the outcomes of early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer compared with paclitaxel when delivered in a neoadjuvant setting. nab 32-35 erb-b2 receptor tyrosine kinase 2 Homo sapiens 105-139 29327055-4 2018 Objective: To determine whether nab-paclitaxel improves the outcomes of early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer compared with paclitaxel when delivered in a neoadjuvant setting. nab 32-35 erb-b2 receptor tyrosine kinase 2 Homo sapiens 141-146 30150888-1 2018 Aim of the study: This study aimed to assess the efficacy of anthracycline-based (AB) and non-anthracycline-based (nAB) adjuvant therapies in the human epidermal growth factor receptor 2 (HER2)-positive non-metastatic BC (nMBC) patients. nab 115-118 erb-b2 receptor tyrosine kinase 2 Homo sapiens 152-186 30150888-1 2018 Aim of the study: This study aimed to assess the efficacy of anthracycline-based (AB) and non-anthracycline-based (nAB) adjuvant therapies in the human epidermal growth factor receptor 2 (HER2)-positive non-metastatic BC (nMBC) patients. nab 115-118 erb-b2 receptor tyrosine kinase 2 Homo sapiens 188-192 27920708-6 2016 CONCLUSION: A multidisciplinary approach to local control and attenuated doses of nab-paclitaxel and trastuzumab suggest a durable response to HER-2-positive breast cancer with cutaneous metastasis. nab 82-85 erb-b2 receptor tyrosine kinase 2 Homo sapiens 143-148 28413662-3 2017 Based on these results, a phase I study of combination therapy with nab-paclitaxel, carboplatin and trastuzumab was planned, in order to estimate its efficacy and safety for HER2-overexpressing locally advanced breast cancer. nab 68-71 erb-b2 receptor tyrosine kinase 2 Homo sapiens 174-178 29285378-14 2017 Thus, neoadjuvant therapy with FEC followed by nab-PTX for operable HER2-negative breast cancer was found to be a safe and effective option. nab 47-50 erb-b2 receptor tyrosine kinase 2 Homo sapiens 68-72 28701571-2 2017 We evaluated nab-Paclitaxel efficacy as neoadjuvant treatment for early estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) disease. nab 13-16 erb-b2 receptor tyrosine kinase 2 Homo sapiens 112-146 28256066-0 2017 Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. nab 29-32 erb-b2 receptor tyrosine kinase 2 Homo sapiens 88-92 27831502-7 2017 In HER2+/HR+ tumors, the pCR rate was 52.9% (49.7% Pac, 56.4% nab-Pac). nab 62-65 erb-b2 receptor tyrosine kinase 2 Homo sapiens 3-7 27919976-0 2016 Phase I Study of Triweekly Nab-Paclitaxel Combined with S-1 in Patients with HER2-negative Metastatic Breast Cancer. nab 27-30 erb-b2 receptor tyrosine kinase 2 Homo sapiens 77-81 27171333-6 2016 Upon identification of an ERBB2 gene amplification within the NCT MASTER (Molecularly Aided Stratification for Tumor Eradication Research) exome sequencing program with resulting overexpression of HER2 in the tumors cells, the patient received a targeted therapy with the HER2 antibodies pertuzumab and trastuzumab in combination with nab-paclitaxel, which led to a durable remission for more than one year. nab 335-338 erb-b2 receptor tyrosine kinase 2 Homo sapiens 26-31 26673577-3 2015 nab-paclitaxel-based regimens (with gemcitabine or carboplatin+-bevacizumab) also demonstrated efficacy and safety in first-line phase II trials of human epidermal growth factor receptor 2-negative metastatic breast cancer. nab 0-3 erb-b2 receptor tyrosine kinase 2 Homo sapiens 154-188 25579459-9 2015 The present study evaluated the activity and safety of nab-PTX as a neoadjuvant treatment of HER2(+) breast cancer. nab 55-58 erb-b2 receptor tyrosine kinase 2 Homo sapiens 93-97 26029934-3 2015 OBJECTIVE: To report on experience with nab-paclitaxel for human epidermal growth factor receptor 2 (HER2)-negative MBC and identify patient characteristics affecting nab-paclitaxel treatment patterns in the community practice setting. nab 40-43 erb-b2 receptor tyrosine kinase 2 Homo sapiens 65-99 26029934-3 2015 OBJECTIVE: To report on experience with nab-paclitaxel for human epidermal growth factor receptor 2 (HER2)-negative MBC and identify patient characteristics affecting nab-paclitaxel treatment patterns in the community practice setting. nab 40-43 erb-b2 receptor tyrosine kinase 2 Homo sapiens 101-105 26029934-13 2015 CONCLUSIONS: In the community setting, nab-paclitaxel 100 mg/m2 weekly was the most commonly used starting dose for patients with HER2-negative MBC, including those with aggressive disease characteristics. nab 39-42 erb-b2 receptor tyrosine kinase 2 Homo sapiens 130-134 25931813-14 2015 CONCLUSION: Our results showed that single-agent nab-paclitaxel 260 mg/m(2) every 3 weeks is an effective and well tolerated regimen as second-line chemotherapy in HER2-negative, taxane-pretreated MBC patients, and that it produced interesting values of objective response rate and progression-free survival without the concern of significant toxicity. nab 49-52 erb-b2 receptor tyrosine kinase 2 Homo sapiens 164-168